November 22, 2016 - By Marie Mckinney · 0 Comments
The stock of Xtl Biopharmaceuticals Limited Ads (NASDAQ:XTLB) registered an increase of 46.55% in short interest. XTLB’s total short interest was 8,500 shares in November as published by FINRA. Its up 46.55% from 5,800 shares, reported previously. With 50,000 shares average volume, it will take short sellers 0 days to cover their XTLB’s short positions. The short interest to Xtl Biopharmaceuticals Limited Ads’s float is 0.09%. The stock decreased 13.58% or $0.11 on November 21, hitting $0.7. X T L Biopharmaceuticals Ltd (ADR) (NASDAQ:XTLB) has declined 35.78% since April 20, 2016 and is downtrending. It has underperformed by 40.34% the S&P500.
XTL Biopharmaceuticals Ltd. is a biopharmaceutical company. The company has a market cap of $10.62 million. The Firm focuses on the acquisition and development of pharmaceutical drugs for the treatment of medical needs. It currently has negative earnings.
Insitutional Activity: The institutional sentiment increased to 2 in 2016 Q2. Its up 1.67, from 0.33 in 2016Q1. The ratio is positive, as 1 funds sold all X T L Biopharmaceuticals Ltd (ADR) shares owned while 2 reduced positions. 0 funds bought stakes while 1 increased positions. They now own 1.13 million shares or 4.59% less from 1.19 million shares in 2016Q1.
Tower Rech Ltd Liability (Trc) has 0% invested in the company for 600 shares. Morgan Stanley, a New York-based fund reported 600 shares. Sabby has 0.06% invested in the company for 1.00 million shares. Invesco owns 129,811 shares or 0% of their US portfolio.
XTL Biopharmaceuticals Ltd., incorporated on March 9, 1993, is a biopharmaceutical company. The Firm focuses on the acquisition and development of pharmaceutical drugs for the treatment of medical needs. The Company’s products include hCDR1 and Recombinant Human Erythropoietin (rHuEPO).
Another recent and important X T L Biopharmaceuticals Ltd (ADR) (NASDAQ:XTLB) news was published by Prnewswire.com which published an article titled: “Strategic Online Marketing Agreement signed by InterCure, XTL …” on September 24, 2012.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.
By Marie Mckinney